Verrica's wart treatment sales climb to $6.9M quarterly total as late-stage trial recruitment closes
Verrica Pharmaceuticals says US sales of its molluscum therapy YCANTH grew almost 58% in the third quarter, while it also drew down the rest of its credit line.
Verrica Pharmaceuticals posted third-quarter 2026 figures on 12 November showing US net product revenue of $5.7M from YCANTH, 57.9% higher than in the same period of 2025. Total revenue for the quarter came to $6.9M.
The company also said it has finished enrolling patients in the first of two pivotal Phase 3 studies testing YCANTH in common warts. Topline results from that study are expected in the first quarter of 2027, and the second study is scheduled to report around mid-2027. Success would open a path to a second indication for a product already on the US market.
On financing, Verrica said it has accessed the remaining $15.0M of a $27.5M credit facility, so the full amount is now available to it. The company is also looking at VP-315 as a possible treatment for Gorlin syndrome.
The information available does not cover the design or endpoints of the warts trials, the terms attached to the credit facility, or the plans for Gorlin syndrome. Those details would need to be confirmed in Verrica's full results documents.
Why it matters
- The 57.9% annual rise in YCANTH net product revenue offers a current reference point on US uptake for market-access teams.
- Two readouts, in Q1 2027 and mid-2027, will determine whether a common warts label expansion is viable; regulatory teams may want to watch for any filing plans that follow.
- With the full $27.5M credit facility now accessible, Verrica has more funding in hand while its late-stage programmes run, though the terms were not disclosed.
- VP-315 in Gorlin syndrome is only being explored, so it carries no regulatory milestones to track yet.
Company's press release (SEC filing): Verrica Pharmaceuticals Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
